Longevity Receives Grant to See if Its Nerve-cell-protecting Therapy Will Work in MS

Longevity Biotech has received a $316,384 grant from the National MS Society to see if LBT-3627. the nerve cell-protecting therapy it has tested in Parkinson’s, can work in multiple sclerosis as well.

The company designed the therapy to protect and repair damaged nerve cells and restore balance to the out-of-whack immune response associated with neurodegenerative diseases such as MS.

“We are thrilled to work with the National MS Society on this project to evaluate the performance of LBT-3627 as the basis of a new therapeutic strategy addressing the debilitating unmet needs of the millions of MS patients,” Dr. Scott Shandler, Longevity’s CEO, said in a press release.

Continue

MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services.